Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)

NCT01498419 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

207

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Tuberculosis

Interventions

DRUG: Moxifloxacin (M)
DRUG: Pretomid (Pa)
DRUG: Pyrazinamide (Z)
DRUG: Rifafour

Sponsor

Global Alliance for TB Drug Development